Inventiva (NASDAQ:IVA) Shares Gap Up – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s share price gapped up prior to trading on Monday. The stock had previously closed at $3.68, but opened at $3.81. Inventiva shares last traded at $3.5950, with a volume of 236,477 shares traded.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IVA. Truist Financial raised their price objective on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings cut shares of Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Finally, Piper Sandler reissued an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Inventiva presently has an average rating of “Moderate Buy” and an average target price of $14.67.

Check Out Our Latest Research Report on Inventiva

Inventiva Stock Performance

The company has a 50-day moving average of $3.58 and a 200 day moving average of $4.72.

Inventiva (NASDAQ:IVA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The business had revenue of $0.75 million during the quarter. As a group, equities research analysts predict that Inventiva S.A. Sponsored ADR will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IVA. Platt Investment Counsel LLC bought a new stake in Inventiva during the third quarter valued at approximately $45,000. China Universal Asset Management Co. Ltd. grew its stake in Inventiva by 78.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock worth $142,000 after buying an additional 17,000 shares in the last quarter. Engineers Gate Manager LP increased its holdings in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after buying an additional 43,280 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Inventiva in the 3rd quarter worth $306,000. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock worth $332,000 after buying an additional 5,857 shares during the last quarter. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

(Get Free Report)

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.

Further Reading

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.